These tests can be completed with CDX2 and CK19 for upper gastrointestinal tract, biliary ducts and pancreas, thyroglobulin for thyroid adenocarcinoma, NY-BR-1 and GATA-3 for female breast cancer, Mel-A, S100 and HMB45 for melanoma, and vimentin and Mel-A for kidney and adrenal gland tumors. This evidence concerns the gene KRT19 and breast carcinoma.